

Title Page

Title: Whole Exome Sequencing Reveals *FCGBP* Variant Associated with Spontaneous Intraabdominal Hemorrhage in Severe Acute Pancreatitis

Authors and affiliations

Qiu-Yi Tang^{1,2,3,†}, Yue-Peng Hu^{2,†}, Qi Yang², Jing Zhou^{1,2}, Jing-Zhu Zhang², Jie Yang², Haibin Hao², Gang Li², Bai-Qiang Li², Lu Ke², Zhi-Hui Tong^{1,2}, Yu-Xiu Liu², Evan Yi-Wen Yu^{4,5,**}, Wei-Qin Li^{1,2,*}

¹ School of Medicine, Southeast University, Nanjing 210009, China.

² Department of Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China.

³ Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.

⁴ Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, and Department of Epidemiology & Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China.

⁵ Department of Epidemiology, CAPHRI Care and Public Health Research Institute, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht 6229ER, the Netherlands.

† These authors contributed equally to this work.

Correspondence to

*Wei-Qin Li, M.D.

Phone number: +86-025-0860007, Fax: +86-025-80860007.

Email: liweiqindr@nju.edu.cn

Mailing address: No. 305 Zhongshan East Road, Nanjing 210002, China.

&

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
**Evan Yi-Wen Yu, Ph.D.

Phone number: +31 06 13155188

E-mail address: evan.yu@maastrichtuniversity.nl

Mailing address: 87 Ding Jiaqiao, Nanjing 210009, China

ORCID: <https://orcid.org/0000-0001-7825-5087>

Ethics statements

Patient consent for publication

All participants were informed about the purpose of study during the admission interview, with consent prior to enrolling in the study.

Ethics approval

The study design and conduction complied with all relevant regulations regarding the human participants and was in accordance with the criteria set by the Declaration of Helsinki. The study's protocol was approved by the Ethics Committee of Jinling Hospital, Nanjing, China (ref. No. 2021NZKY-042-01).

All animal experiment procedures followed Chinese Animal Welfare Act, the Guidance for Animal Experimentation of Southeast University. Efforts were made to minimize the number of animals used and reduce their suffering (ref. No. 2022DZGKJDWLS-0059).

Declaration of interests

The authors declare no competing interests.

Author contributions

Conceived and designed the study: Q.Y.T, E.Y.Y; supervision: E.Y.Y, W.Q.L; conducted data analyses and interpretation and drafted the manuscript: Q.Y.T; data curation: Q.Y.T, Y.P.H, Q.Y; conducted experiments: Y.P.H, Q.Y.T; critical revision of the manuscript: E.Y.Y, W.Q.L, L.K, Y.X.L, J.Z, J.Z.Z, J.Y, H.B.H., G.L, B.Q.L, Z.H.T. All authors read and approved the final manuscript.

Data and code availability

The original data and codes used for the current study are available upon reasonable request. The raw sequencing data reported in this study have been being deposited and will be publicly available after this paper is published. All data are provided within the article.

Highlights

- Genetic mutation in *FCGBP* presents a strong association with predisposition of spontaneous intraabdominal hemorrhage, and provide a novel insight in increasing the severity of acute pancreatitis when knockdown the expression of *Fcgbp*.
- The incorporation of *FCGBP* mutation as an indicator enhances the ability of clinical assessment with respect to complications and mortality of acute pancreatitis in an early phase before manifestation.
- Our findings highlight the gene *FCGBP* as a probable pathogenic cause of spontaneous intraabdominal hemorrhage in severe acute pancreatitis patients, which enable a development of effective targeted therapies in improving the prognosis and critical care of severe acute pancreatitis.

1 **Abstract**

2 This study sought to identify genetic cause of spontaneous intraabdominal hemorrhage
3 (SIH) in severe acute pancreatitis (SAP) to develop more effective treatment for this
4 life-threatening complication. A four-phase study was conducted, leveraging a large-
5 scale acute pancreatitis (AP) patients (n=600); the first phase involved whole-exome
6 sequencing analyses, and identified specific exonic variant located in *FCGBP* (i.e.,
7 rs1326680184) that was consistently associated with SIH; the second phase performed
8 serum ELISA tests, and revealed that *FCGBP* variant altered FCGBP level and further
9 led to predisposition of SIH; the third phase conducted an i) *in-vivo* experiment with a
10 *Fcgbp*-knockdown mouse model, and demonstrated lower expression of *Fcgbp* led to
11 more severe AP morphology and higher risk of hemorrhage; ii) *in-vitro* experiment with
12 *FCGBP*-knockdown human vascular fibroblasts demonstrated that down-regulated
13 *FCGBP* expression could destabilize the vascular wall, and lead to vascular injury in
14 SAP; the fourth phase compared *FCGBP* variant carriers to non-carriers with clinical
15 characteristics, and found *FCGBP* variant associated with higher risks of poor
16 complications and AP prognosis and enhanced the diagnostic capability as an indicator.
17 These findings provide important insights into the underlying mechanism of SIH in
18 SAP, and facilitate therapeutic development for AP prognosis and critical care in an
19 early phase.

20

- 1 **Keywords:** Spontaneous intraabdominal hemorrhage; Acute pancreatitis; Whole
- 2 exome sequencing; Gene-prognosis association

1 **Introduction**

2 Acute pancreatitis (AP), an acute inflammatory condition of pancreas, has become one
3 of the leading causes of acute abdominal diseases. The annual incidence of AP ranges
4 from 13 to 45 per 100,000 people, with approximately 20.0% progressed to severe
5 outcomes and even death.^{1,2} The mortality of AP, as pooled from population-based
6 cohort studies, is 1.16 per 100,000 general population per year.³ Nevertheless, the
7 severe form of AP (SAP), which can lead to complications such as infected pancreatic
8 necrosis (IPN) and acute respiratory distress syndrom (ARDS), has been reported to be
9 associated with a high mortality rate over 30.0%.⁴ Unfortunately, there are currently no
10 therapeutic agents available that can alter the course of AP, and the mechanisms of
11 those complications remain largely unknown.

12 As one of the life-threatening complications, intraabdominal hemorrhage occurs during
13 the course of AP, particularly SAP, and results in an elevated risk of abdominal
14 infection, multiple organ dysfunction and other fatal consequences. While
15 multifactorial characteristics, e.g., progressive inflammation, portal hypertension,
16 necrosis and surgical necrosectomy, have been reported to be related to intraabdominal
17 hemorrhage,⁵ the evidence remains controversial. The causes and pathogenesis of
18 intraabdominal hemorrhage, particularly of spontaneous intraabdominal hemorrhage
19 (SIH), have not been well understood. SIH is a critical form of intraabdominal
20 hemorrhage that occurs in the course of AP without prior surgical intervention to the
21 pancreas, making it difficult to be recognized and managed in the early phase of AP.

1 According to Chen *et al.*,⁶ AP patients complicated with SIH had a worse prognosis,
2 with a higher mortality (54.2%) than those without SIH (20.8%). Therefore, identifying
3 high-risk AP patients before this condition manifest is crucial. To our best knowledge,
4 merely studies have investigated SIH in AP patients, while the risk factors and
5 underlying mechanisms remain largely unknown. Given that previous studies have
6 raised the suggestions for genetic variants as causative factors for several complications
7 of AP,⁷⁻¹¹ the role of genes, therefore, may be essential in the development of SIH.
8 In the past decade, next-generation sequencing techniques, including whole exome
9 sequencing (WES), has been increasingly used to investigate genetic causes in complex
10 diseases, particularly for agnogenic phenotypes.¹² WES offers significant value in
11 addressing unexplained presumed disorders by providing an opportunity to investigate
12 potentially actionable variants and maximize clinical and biological exploration. This
13 approach can guide clinical decision-making and provide valuable insights for selected
14 experimental follow-up. Here we sought to use the largest WES study to date of AP to
15 investigate the disease-specific influence of exonic variants on SIH to unveil potential
16 cause and mechanism involved in SIH, thereby facilitating a more effective strategy for
17 AP prognosis and critical care.

18

19 **Methods**

20 ***Participants enrollment***

1 All the patients related to AP and admitted to Jinling Hospital, a tertiary level referral
2 center in Nanjing, China, from 1st January 2015 to 31st December 2020, were
3 retrospectively reviewed for eligibility in this study. All participants were informed
4 about the study's purpose during the admission interview and provided with consent
5 prior to enrollment. The study design and conduct complied with all relevant
6 regulations regarding the use of human participants and was in accordance with the
7 criteria set by the Declaration of Helsinki. The study protocol was approved by the
8 Ethics Committee of Jinling Hospital, Nanjing, China (ref. No. 2021NZKY-042-01).

9 To definitude SAP complicated with SIH (i.e., SIH-SAP), all the participants were
10 assessed according to stringent inclusion and exclusion criteria For inclusion criteria; i)
11 diagnosed as AP according to the revised Atlanta criteria (RAC),¹³ ii) attributed as
12 severe or critical AP according to determinants-based classification (DBC) guideline,¹⁴
13 iii) presence of intraabdominal hemorrhage on contrast-enhancing computed
14 tomography without prior invasive intervention. For exclusion criteria; i) participants
15 who had a history of hemophilia, idiopathic thrombocytopenic purpura, abdominal
16 aorta aneurysm, or other hemorrhage associated disorders, ii) who received
17 anticoagulation therapies within a week before admission.

18 The primary control group of SAP patients without SIH (i.e., non-SIH-SAP) was
19 selected using a 1:1 ratio propensity score matching (PSM) based on the severity of AP.
20 The severity was quantified based on Acute Physiology and Chronic Health Evaluation
21 II (APACHE II) score and classified as mild, moderate, severe or critical according to

1 DBC guideline.¹⁴ Additionally, to further validate the generalizability and stability of
2 identified signals in SIH-SAP patients, a secondary control group was established
3 consisting of AP patients without SIH (i.e., non-SIH-AP). Since 4 patients rejected to
4 sign the informed consent form for using their blood to conduct WES, a total of 45 SIH-
5 SAP patients, 45 non-SIH-SAP patients, and 510 non-SIH-AP patients were included
6 in the current study. Clinical and anthropometric information were obtained from
7 medical interviews, physical examinations and laboratory assessments at admission.

8 *Whole exome sequencing*

9 Peripheral blood samples were collected within one day after admission and stored at -
10 80°C. Genomic DNA of all participants was extracted from stored peripheral blood
11 using TIANGEN kit (Beijing, China), following the manufacturer's protocols. Whole-
12 exome libraries were generated according to the manufacturer's protocols, with
13 enrichment of exon-coding regions using Agilent's V6 capture reagent (Agilent
14 Technologies, Santa Clara, CA). Paired-end (2×150 base pairs) sequencing was
15 performed on Illumina NovaSeq 6000 System (Illumina, San Diego, CA) (please see
16 details in Supplementary methods).

17 *Variant-based analysis*

18 After quality control and variant screening (as described in supplementary methods), a
19 total of 1,322 candidate variants, including the uncommon variants (MAF <0.01) and
20 variants without population allele frequency annotation, were selected for further analysis
21 due to their potential pathogenic implications. Here, the candidate variants with

1 different allele frequency between the case group (45 SIH-SAP patients) and the
2 primary control group (40 non-SIH-SAP patients) were identified as probable
3 pathogenic variants at $p_{\text{fdr}} < 0.05$ (*Fisher's* exact method of R package “*stats*” and FDR
4 correction with Benjamini-Hochberg method). In addition, the secondary control group
5 consisting of 510 non-SIH-AP patients, was used to validate the identified exonic
6 variants, in which the *Fisher's* exact method was performed to assess the distribution
7 of allele frequency compared to the case group of 45 SIH-SAP patients at $p_{\text{fdr}} < 0.05$.
8 As a sensitivity analysis, all the 1,037,733 variants that passed quality control were also
9 performed variant-based analysis according to the process mentioned above.

10 *Targeted genome-wide association analysis*

11 Based on the identified signals, a chromosome-19-specific analysis was performed to
12 minimize the effects of genome-wide multiple testing. The high-quality variants from
13 the case (i.e., SIH-SAP) group and control (i.e., non-SIH-SAP) group underwent
14 stringent quality control measures and were subsequently merged. The variants from
15 both case and control groups were filtered using PLINK (version 1.9.0)¹⁵ to ensure
16 reliability. A total of 43,486 variants located in chromosome 19 were deemed eligible.
17 Samples were excluded if they failed genotyping in more than 40% of variants. The
18 variants were excluded if they met any of the following criteria: i) call rate <60%; ii)
19 MAF <0.01; iii) significantly deviated from Hardy-Weinberg equilibrium (HWE) with
20 $p < 1 \times 10^{-8}$.¹⁶ The significance threshold was set at an exome-wide level of $p < 5 \times 10^{-6}$
21 ($1 \times 10^{-8}/1\%$, as exome accounts for approximately 1% of human genome). PLINK

1 (version 1.9.0) was used to perform this chromosome-19-specific targeted genome-
2 wide association analysis, controlling for age (years) and gender (male or female) as
3 covariates. Also, an exome-wide association analysis was performed with variants
4 detected across all chromosomes to account for any unexpected signals, applying the
5 same statistical models and criteria used in the chromosome-19-specific analysis.

6 *Gene-based analysis*

7 Variants with $MAF < 0.01$ or lacking allele frequency information in genome reference
8 databases (i.e., Exome Aggregation Consortium and 1000 Genomes) and predicted to
9 be deleterious, were subjected to gene annotation. A sequence kernel association test
10 (SKAT),^{17,18} a gene-based analysis, was employed to explore the associations between
11 genes containing at least two exonic variants, such as *FCGBP*, and development of SIH
12 in all the included participants. Since not all the variants defined as “uncommon” have
13 a $MAF < 1\%$ in our SIH-SAP patient group, a different approach was applied, which is
14 to define the variants with $MAF \leq 1 / \sqrt{2n}$ as “uncommon” whereas variants with
15 $MAF > 1 / \sqrt{2n}$ as “common” (n is the total sample size).¹⁷ The combined effects of
16 uncommon and common exome variants on SIH were assessed by using R package
17 “*SKAT*”.

18 *Experiments*

19 All animal experiment procedures followed Chinese Animal Welfare Act, the Guidance
20 for Animal Experimentation of Southeast University. Efforts were made to minimize
21 the number of animals used and reduce their suffering (ref. No. 2022DZGKJDWLS-

1 0059). Male ICR mice aged 8 weeks were obtained from Ziyuan Laboratory Animal
2 Technology Co., Ltd. (Hangzhou, China). Animals were housed and maintained in
3 specific pathogen-free (SPF) facilities with a 12-hour light-dark cycle and free access
4 to standard food and water.

5 *Knock-down of Fcgbp*

6 *Fcgbp* was silenced using an adeno-associated virus (AAV) vector delivery system. An
7 AAV vector harboring a short hairpin RNA (shRNA) targeting *Fcgbp* (Refseq
8 NM_001122603.1) (AAV-RNAi) was provided by Gene Chem Co., Shanghai, China.
9 For *Fcgbp*-target AAV-RNAi packaging, the designed shRNA primers (Supplementary
10 Table 1) were inserted into the vector. The titer of AAV was 3.36×10^{13} viral genome
11 copies per ml, and a total of 5.00×10^{11} viral genome copy was infused through
12 intravenous injection per mouse.

13 *In-vivo acute pancreatitis mice model*

14 The SAP mouse model was induced by intraperitoneal injection of caerulein (50 $\mu\text{g}/\text{kg}$
15 for 7 times with one-hour intervals) followed by lipopolysaccharide (administered one
16 hour after the final caerulein injection at 5mg/kg, one time).¹⁹ The pathological
17 examination of pancreas in SAP mice and normal mice are presented in Supplementary
18 Fig. 1. The blood assays for $\text{TNF}\alpha$, IL-6, MCP1 are provided in Supplementary Fig. 2.
19 The *Fcgbp-KD* mice, together with the mice injected with either the AAV vector or
20 PBS, were induced as SAP on the 30th day since the day of AAV or PBS injection (n=10
21 for each group). At 24h post-SAP induction, the mice were anesthetized, and tissues of

1 lung, pancreas, colon, and vessel were harvested before the mice were sacrificed with
2 minimal suffering.

3 *Immunohistochemistry*

4 Immunohistochemistry (IHC) was performed to in terms of Fc Fragment of
5 Immunoglobulin G Binding Protein (Fcgbp) in lung, colon and vessel tissues that were
6 obtained from the sacrificed mice. Briefly, 5- μ m-thick cryosections of quick-frozen
7 lung, colon and vessel tissues were fixed in acetone, quenched with 3% H₂O₂, and
8 blocked with goat serum. After washes with PBS, the sections were treated with anti-
9 *Fcgbp* primary antibody (bs-13168R, Bioss, Beijing, China) for 2 hours. Then, the
10 sections were incubated with horseradish-peroxidase-conjugated secondary antibody
11 for an hour. Color development was achieved using 3,3'-diaminobenzidine tetra
12 hydrochlorides as peroxidase substrate. The proportion of Fcgbp with positive response
13 was quantified using ImageJ. The difference of positive areas in three groups (i.e.,
14 control, AAV-RNAi and AAV vector groups) were compared using one-way ANOVA
15 with post-hoc testing to evaluate the significance of difference among three groups.

16 *Immunofluorescence*

17 Immunofluorescence was conducted in terms of Fcgbp, Cd31, α -Sma, and Vegf in
18 vessel tissues that were obtained from the sacrificed mice. The procedure followed the
19 same initial steps as immunohistochemistry up to the secondary antibody incubation.
20 After washing three times with PBS, the tissue was reacted with fluorescent dye.

21 *Morphological examination*

1 Fresh pancreatic and pulmonary tissue samples were fixed with 4% paraformaldehyde
2 overnight. After fixation, the samples were washed with running water for 2 hours,
3 dehydrated with a gradient of ethanol, embedded in paraffin, and then cut into 5- μ m-
4 thick sections. The sections were dewaxed in xylene, rehydrated through downgrade
5 ethanol solutions (100%, 95%, 80%, 70%), and stained with hematoxylin and eosin.
6 Morphological examination, including edema area and grade, acinar cell necrosis,
7 inflammatory reaction, adipose necrosis, and hemorrhage, was assessed to determine
8 the severity of AP for each group in mice (n=10 per group) by two independent and
9 blinded investigators using previously reported morphometry methods.²⁰ The
10 differences of severity scores among the three groups were evaluated using one-way
11 ANOVA with post-hoc tests.

12 *Cell lines and cultures*

13 Cell line of human vascular fibroblast was obtained from Wuhan Sunncell Biotech Co.,
14 Ltd. (SNP-H362, Hubei, China) and cultured in a specific complete culture medium
15 provided by Wuhan Sunncell Biotech Co., Ltd. (SNPM-H362, Hubei, China). The cells
16 were maintained in a 5% CO₂ humidified incubator at 37°C in media supplemented
17 with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) and 1% penicillin and
18 streptomycin (Gibco, Grand Island, NY, USA).

19 *Construction of knockdown cell*

20 Cells designated for knockdown construction were thoroughly digested and plated in
21 6-well plate at a density of 70–80%. *FCGBP*-targeting siRNAs were then introduced

1 and incubated. The efficiency of the knockdown was assessed by qRT-PCR and western
2 blot analysis.

3 *RNA-Seq and bioinformatics analysis*

4 Total cellular RNA was extracted from both the knockdown fibroblasts and the wild-
5 type controls, with residual DNA removed using DNase I (Roche Diagnostics). RNA-
6 seq libraries were prepared using the TruSeq RNA Library Prep Kit and sequenced on
7 the Illumina NextSeq 500 platform. The resulting data were processed to compute
8 transcript FPKMs. Pathway analysis was performed using the GO
9 (<http://geneontology.org/>) and KEGG (<https://www.genome.jp/kegg/>) databases.

10 ***Investigation of identified variant to clinical characteristics***

11 AP patients in case group, primary control group, and secondary control group were
12 pooled (n=600) irrespective of disease severity and presence of SIH. These patients
13 were then re-categorized according to genetic status of the identified variant as carriers
14 or non-carriers. To link the identified variant(s) to clinical characteristics, analyses were
15 conducted comparing variant carriers to non-carriers. This involved comparing the
16 distribution of clinical characteristics and testing their associations with the identified
17 variant using a standard logistic regression adjusted for age (years, continuous), gender
18 (male or female), BMI (Kg/m², continuous) and etiology of AP (biliary,
19 hypertriglyceridemia, and others). Blood test parameters were measured during the first
20 blood draw upon admission to the hospital. The receiver operating characteristic curve
21 (ROC) (R package “*pROC*”),²¹ and DeLong’s test²² for comparison of area under the

1 ROC curve (AUROC) were employed to assess whether the identified variant increase
2 the diagnostic ability for a series of clinical outcomes, including SIH, in addition to
3 demographic and clinical factors.

4 ***Statistical analysis***

5 Descriptive statistics are presented as median (interquartile range) for continuous
6 variables and frequency (percentage, %) for categorical variables. Demographic and
7 clinical characteristics between different groups of participants were compared by
8 Wilcoxon rank-sum test for continuous variables, and *Fisher's* exact test for categorical
9 variables. All the statistical analyses were performed using R software 4.1.0 (R Core
10 Team. R Foundation for Statistical Computing. Vienna, Austria. 2021. [https://www.R-](https://www.R-project.org)
11 [project.org](https://www.R-project.org)).

12 ***Statistical power and multiple hypothesis testing***

13 To minimize the occurrence of false discoveries, the current study utilized a series of
14 measures as: i) genetic variants with relatively low reliability were eliminated based on
15 quality indicators including missing rate, quality score, and VQSR; ii) a filtration
16 strategy was applied to restrict the number of variants tested, excluding common and
17 synonymous variants; iii) a false discovery rate correction was used to account for
18 multiple testing in the comparison of allele frequency distribution among the included
19 candidate variants; iv) to ensure the reliability and reproducibility, the aforementioned
20 analyses were replicated with a secondary control group of non-SIH-AP patients to
21 verify the consistency of the identified genetic signals.

1

2 **Results**

3 *Demographic and clinical characteristics of included participants*

4 A detailed description of the study design, workflow, and data processing is displayed
5 in Fig. 1. Among patients admitted with AP to a tertiary medical center (Jinling hospital,
6 Nanjing, China), a total of 49 patients were determined in a severe or critical scenario
7 of AP and diagnosed with SIH (SIH-SAP). No pedigree relatedness was observed
8 according to the lineage data gained from all included participants. The primary control
9 group of SAP patients without SIH (non-SIH-SAP) was selected using a 1:1 ratio
10 propensity score matching (PSM) based on severity of AP, which were quantified using
11 the Acute Physiology and Chronic Health Evaluation II (APACHE II) score and
12 classified as mild, moderate, severe or critical according to determinants-based
13 classification (DBC) guideline.¹⁴ As showed in Table 1, no difference between the case
14 group (i.e., SIH-SAP patients) and the primary control group (i.e., non-SIH-SAP
15 patients) in terms of the median of APACHE II score (15.00 vs. 15.00), incidence rates
16 of acute kidney injury (80.0% vs. 68.8%) and acute respiratory distress syndrome (82.2%
17 vs. 80.0%) were observed. The median (interquartile range) age at admission was 46
18 (33–56) years for the case group, and 38 (30–44) years for the primary control group
19 ($p=0.007$). Females comprised 17.8% of the case group and 46.7% of the primary
20 control group ($p=0.006$). The mortality rate of SIH-SAP patients (35.6%) is extensively
21 higher than that of non-SIH-SAP patients (22.2%), while no significant difference was

1 observed. In addition, results of coagulation functional test showed a higher thrombin
2 time (median seconds; interquartile range) in the case group (17.00; 15.90–18.30) than
3 the primary control group (15.70; 14.80–17.40; $p=0.027$), and a lower serum fibrinogen
4 (median g/L, interquartile range) in the case group (4.09; 2.76–4.79) than the primary
5 control group (4.56; 3.84–5.90; $p=0.022$). The results of thrombin time indicated SIH-
6 SAP patients tended to have a fibrinogen deficiency or dysfunctional fibrinogen;
7 similarly, the lower serum fibrinogen, a precursor of fibrin that is crucial for formation
8 of blood clot in tissue or vascular injury, suggested a lightly poorer coagulation function
9 of SIH-SAP patients.

10 ***Whole exome sequencing and candidate variants selection***

11 Except for the sequencing data of 5 patients in the primary control group that failed to
12 meet the quality requirements and thereby were removed out of the WES analysis, all
13 the rest of samples produced high-quality WES data with >80.0% of quality score \geq Q30
14 (99.9% of base call accuracy; Supplementary Table 2). On average, 41 million reads
15 per sample (range 35–51 million) were generated, each with an average read length of
16 150bp. Over 99.9% of reads for each sample were on target and 8,334,678 variants
17 were obtained. Nevertheless, a total of 1,037,733 variants (12.5%) remained after
18 quality control. Those variants were then annotated and screened for variants of interest
19 (i.e., minor allele frequency (MAF) <1% and nonsynonymous), which maintained
20 1,322 candidate variants for further analyses (Fig. 2A). Principal components analysis

1 revealed a homogenous population structure between the SIH-SAP patients and non-
2 SIH-SAP patients ($p=0.633$) (Fig. 2B).
3 Nearly 22.3% (i.e., 295 variants) were predicted to be “probably deleterious” or
4 “possibly deleterious” based on Sorting Intolerant from Tolerant algorithm (SIFT) (Fig.
5 2C), and 16.6% (i.e., 220 variants) were predicted to be “probably damaging” or
6 “possibly damaging” based on Polymorphism Phenotyping (PolyPhen). The average
7 number of candidate variants per sample was 461, with *FCGBP* having the highest
8 number of variants among the set of variants analyzed (Fig. 2D). Comprehensive
9 annotation of the candidate variants (Supplementary Table 3-12), the majority of 1,322
10 candidate variants were classified as missense (63.8%), followed by in-frame
11 deletion/insertion (20.0%) and frame-shift deletion/insertion (13.9%). Many of these
12 variants were associated with enhancer histone marks and epigenetic alteration.
13 Specifically, 367 variants were observed to be located in the sites of the CpG island,
14 indicating potential DNA methylation and resulting epigenetic alterations. To
15 biologically understand the genes mapped to identified variants, gene enrichment
16 pathway analyses using GO database identified 68 significant pathways ($p<0.05$),
17 primarily related to metabolism of protein and extracellular matrix organization.

18 ***FCGBP variant associated with SIH-SAP***

19 The allele distribution between the case group (i.e., SIH-SAP) and the primary control
20 group (i.e., non-SIH-SAP) was compared to identify the potential pathogenic variants
21 with significant different alternative allele frequencies between the two patient groups

1 ($p_{\text{fdr}} < 0.05$). Of these candidate variants, rs1326680184, which located in *FCGBP*
2 (Refseq NM_003890), was identified as being associated with SIH development in SAP
3 patients. In contrast to non-SIH-SAP patients (11 out of 40; 27.5%), a significantly
4 higher proportion of SIH-SAP patients were found to harbor the *FCGBP* variant (36
5 out of 45; 80.0%; Fig. 3B). A analysis was conducted using the secondary control group,
6 consisting of 510 AP patients confirmed as non-SIH (i.e., 510 non-SIH-AP patients)
7 from a prospectively-registered cohort of AP patients in our center. The finding was
8 validated by comparing the carriers of rs1326680184 in SIH-SAP patients (36 out of
9 45; 80.0%) and non-SIH-AP patients (192 of 510; 37.6%) ($p_{\text{fdr}} < 0.001$). The
10 identification of the specific *FCGBP* variant maintained consistent when stratified for
11 severity of AP, which indicated a similar carriers for 184 severe or critical AP patients
12 (38.9%) and 326 mild or moderate AP (36.8%, $p > 0.05$), suggesting an extensively
13 conservative effect of the *FCGBP* variant on SIH irrespective of AP severity. Moreover,
14 no additional variants were found to be associated with SIH development in the
15 sensitivity analysis, which included all 1,037,733 variants that passed quality control.
16 To address multiple testing in a relatively small sample size, we employed a targeted
17 GWAS method focusing on signals within chromosome 19, with respect to SIH-SAP
18 patients vs. non-SIH-SAP patients. Again, the identified *FCGBP* variant (i.e.,
19 rs1326680184) was found to be consistently associated with the development of SIH
20 ($p_{\text{adj}} = 3.855 \times 10^{-12}$; Fig. 3C and Supplementary Fig. 3). Moreover, we conducted a
21 whole-exome wide association test by analyzing exome variants across all

1 chromosomes, revealing multiple subtle signals with $p_{\text{adj}} < 5 \times 10^{-6}$ (Supplementary Fig.
2 4).

3 According to genomic annotation, the rs1326680184 is a frameshift deletion located at
4 chromosome 19:39906058-39906060 within the exonic region of *FCGBP*. By using
5 the combined annotation dependent depletion (CADD) score,²³ rs1326680184 was
6 predicted to be deleterious with a scaled C-scores of 20.7, indicating a likely negative
7 effect (Fig. 3D). Additionally, conservative analysis suggests that the regional residues
8 of *FCGBP* are mostly conserved across species and isoforms (Fig. 3E).

9 Through SKAT analysis,^{17,18} 17 genes showed a suggestive association with SIH
10 among SAP patients ($p < 0.01$) (Supplementary Table 13). According to the rank of the
11 number of patients carrying the candidate variants, *FCGBP* was again, identified as the
12 top hit ($p = 1.310 \times 10^{-7}$ in SKAT; Fig. 3F).

13 ***ELISA validation of FCGBP expression affected by FCGBP variant in AP patients***

14 Enzyme-linked immunosorbent assay (ELISA) for FCGBP protein was conducted in
15 peripheral blood of randomly selected AP patients, grouped by the presence (n=27) or
16 absence (n=27) of the rs1326680184 variant. The results showed that AP patients with
17 rs1326680184 had a lower level of FCGBP compared to those without rs1326680184
18 (mean of 2.86 ng/ml vs. 4.66 ng/ml, $p = 0.035$, Fig. 4A). To verify the reduction of
19 FCGBP levels resulting in predisposition of SIH, the comparison of FCGBP protein
20 levels between SIH and non-SIH patients were conducted by grouping the presence
21 (n=30) or absence (n=30) of SIH. The results suggest AP patients with SIH have a

1 significantly lower level of FCGBP ($p < 0.001$, Supplementary Fig. 5), which draw a
2 consistency that *FCGBP* variant alter the FCGBP level, and lower FCGBP level leads
3 to predisposition of SIH.

4 ***Fcgbp knockdown exacerbates the severity and multi-organ injury of AP in mice***

5 A mouse model with *Fcgbp*-knockdown (*Fcgbp-KD*) was conducted through
6 intravenous injection of adeno-associated virus harboring a short harpin RNA targeting
7 *Fcgbp*. Subsequently, in the colon tissue, identified as the most enriched site of *Fcgbp*,²⁴
8 western-blot analysis revealed an average decrease of 41.5% in *Fcgbp* expression in
9 *Fcgbp-KD* mice compared to the normal mice ($p = 0.002$, Fig. 4B & 4C). This reduction
10 in *Fcgbp* expression was consistently confirmed through immunohistochemistry (IHC)
11 staining in colon tissue (Fig. 4D & 4E), lung tissue (Supplementary Fig. 6), and vessel
12 tissue (Supplementary Fig. 7). The *Fcgbp-KD* mice, together with the mice that were
13 injected with AAV vector or phosphate buffer saline as control, were induced to be the
14 SAP model through intraperitoneal injection of caerulein and lipopolysaccharide.
15 Based on pathomorphological examination, the *Fcgbp-KD* mice presented a severer
16 morphology in pancreas tissue and lung tissue compared to the control mice (Figure
17 4E). Particularly, the severity of edema and destruction of alveolar structure was more
18 pronounced in mice where *Fcgbp* was subjected to knockdown. With regards to
19 pancreas, in line with previously established morphometry²⁰ assessment for the severity
20 of AP (Supplementary Table 14), *Fcgbp-KD* mice exhibited more severe edema (3.50
21 vs. 2.63, $p = 0.032$), acinar cell necrosis (1.13 vs. 0.38, $p = 0.005$) and inflammation (3.38

1 vs. 1.25, $p < 0.001$) compared to control mice, suggesting the reduction of Fcgbp may
2 cause a deleterious scenario in pancreas. In addition, the leakage of Erythrocytes into
3 interlobular space of pancreas and pulmonary alveoli was observed in *Fcgbp-KD* mice
4 but absent in control mice, which indicated the decrease of Fcgbp exacerbated the
5 predisposition of vascular injury and hemorrhage (Fig. 4F & 4G).

6 To further explore the protective mechanism of FCGBP against SIH, we initially
7 conducted immunofluorescence analysis on vessel tissues of mice. The results indicated
8 that FCGBP is primarily produced by fibroblasts, as marked by α -Sma (Fig. 5A). We
9 then performed an comprehensive examination of mRNA expression profiles of the
10 *FCGBP*-knockdown fibroblasts compared to wild-type human vascular fibroblasts. We
11 identified 456 genes were up-regulated and 309 genes were down-regulated in *FCGBP*-
12 knockdown fibroblasts (Fig. 5B). Through subsequent enrichment analysis, the down-
13 regulated gene sets were significantly enriched in terms such as “extracellular matrix”,
14 “collagen-containing extracellular matrix”, and “external encapsulating structure” (Fig.
15 5C).

16 ***Association between FCGBP variant of rs1326680184 and clinical characteristics***

17 Out of 600 included participants, a total of 327 AP patients were eligible for further
18 assessment of the association between *FCGBP* variant (e.g., rs1326680184) and
19 clinical characteristics, based on accessibility of complete genotyping, clinical
20 outcomes and laboratory measures. Of these included AP patients, 144 (44.0%) were
21 rs1326680184 carriers while 183 (56.0%) were non-rs1326680184 carriers, who

1 showed no difference on age, gender and BMI. However, the rs1326680184 carriers
2 showed prolonged thrombin time than non-carriers (mean of 19.24s vs. 16.97s;
3 $p=0.010$), which indicated an abnormal coagulation function affected by rs1326680184
4 variant occurred in *FCGBP*. In addition, the rs1326680184 carriers suffered a higher
5 rate of mortality (11.8% vs. 4.4%; $p=0.021$), incidence of acute kidney injury (46.5%
6 vs. 33.5%; $p=0.023$), infected pancreatic necrosis (56.2% vs. 26.9%; $p<0.001$), and
7 critical form of AP (43.1% vs. 20.2%; $p<0.001$) (Fig. 6A; Supplementary Table 15).
8 Those findings support the aforementioned observation that *FCGBP* variant may alter
9 the predisposition of hemorrhage and thereby led to a poorer clinical outcomes of AP
10 patients. Moreover, the rs1326680184 carriers tended to have a lower count of red blood
11 cell (mean of $3.22 \times 10^9/L$ vs. $3.57 \times 10^9/L$; $p<0.001$), hemoglobin concentration (mean
12 of 95.36 g/L vs. 107.30 g/L; $p<0.001$) and hematocrit (mean of 29.0% vs. 30.0%;
13 $p=0.001$) (Supplementary Table 16), providing additional evidence that phenotypes
14 related to SIH were likely to be poorly manifested in the AP patients of presence than
15 absence of *FCGBP* variants.

16 To evaluate the clinically application of *FCGBP* variant rs1326680184, a standard
17 logistic regression was performed in comparison of rs1326680184 carriers to non-
18 carriers. The results revealed the rs1326680184 carriers with an higher risk of SIH
19 development (OR 11.35; 95%CI: 3.66–45.81; $p_{\text{adjust}}<0.001$), severity of AP (OR 3.04;
20 95%CI: 1.65–5.71; $p_{\text{adjust}}<0.001$), and infected pancreatic necrosis (OR 3.77; 95%CI:
21 2.09–6.93; $p_{\text{adjust}}<0.001$), respectively (Fig. 6B). Those findings were validated by

1 using multiple models adjusted for different demographic factors. When compared to
2 the model based on conventional demographic factors (i.e., age, gender, etiology of AP),
3 the additional inclusion of rs1326680184 presented higher performance (i.e., area under
4 receiver operating curve: AUROC) for diagnosing clinical outcomes respectively; SIH
5 (0.84 vs. 0.88, $P_{\text{-DeLong}}=0.011$), IPN (0.61 vs. 0.69, $P_{\text{-DeLong}}=0.002$), severity of AP (0.66
6 vs. 0.7, $P_{\text{-DeLong}}=0.013$), death (0.63 vs. 0.72, $P_{\text{-DeLong}}=0.052$). These results suggest
7 *FCGBP* variants could serve as a competent risk indicator, enhancing the diagnosis of
8 complication and prognosis of AP with stable diagnostic ability (Fig. 6C).

9

10 **Discussion**

11 The current study, by leveraging the largest-scale WES data of AP patients, uncovered
12 novel insights into genetic architecture, biological mechanisms and clinical translations
13 of a life-threatening complication (i.e., SIH), which leads to provide potential
14 implications for critical care of AP.

15 By employing single-variant and gene-based analyses, this study identified the genetic
16 variant located in *FCGBP* are enriched in patients with SAP and SIH. According to *in-*
17 *silico* prediction models, the identified variant was predicted with deleterious effect and
18 indicated an alteration of FCGBP protein levels, which was found to be associated with
19 higher predisposition of SIH, and further related to deleterious laboratory measures and
20 poorer prognosis in the context of AP. Those results were validated through *in-vivo*
21 animal model, which is, the *Fcgbp* knockdown mice showed an increased severity of

1 AP and higher predisposition of SIH, with a lower expression of *Fcgbp* in multiple
2 organs.

3 Despite these findings, the underlying functions and regulatory mechanisms of *FCGBP*
4 have not been studied in depth. In 1997, N. Harada *et al.* demonstrated that human
5 FCGBP, which is widely expressed in systemic mucosa, exhibits mucin-like structure
6 thereby is likely to enhance antigen trapping,²⁴ which implies a pivotal role in immune
7 and inflammatory process. Nevertheless, there is a lack of research providing robust
8 evidence on how FCGBP functions in the human health, both in immune system and
9 non-immune systems. While the majority of published studies were neoplastic
10 diseases^{25 26 27 28} upon FCGBP in relation to tumor screening and prognosis, other
11 studies has indicated that FCGBP is also involved in vascular disorders as i) Gäbel *et*
12 *al.* demonstrated that alteration of genes in relation to angiogenesis including *FCGBP*
13 were positively associated with progression and rupture of abdominal aortic
14 aneurysms;²⁹ and ii) Zhang *et al.* demonstrated *FCGBP* variant was also remarkably
15 involved into the development and prognosis of brain arteriovenous malformation.³⁰

16 For the first time, by using WES based on both variants and gene-set analyses, we
17 detected and strengthened *FCGBP*-relevant variant accompanied with development of
18 SIH in SAP patients. Specifically, we identified a frameshift deletion in *FCGBP* that
19 may lead to an alteration of protein expression. Based on this finding, we proposed a
20 hypothesis that the *FCGBP* variant (i.e., rs1326680184) carrier experience an alteration
21 of FCGBP expression, increasing their susceptibility and predisposition of vascular

1 injury and hemorrhage, which might be induced by a serious scenario (e.g., SAP; Fig.
2 5D). To verify this hypothesis, we used vascular tissue to identify the key cell type as
3 the primary producer of FCGBP based on immunofluorescence analysis. We observed
4 Fcgbp co-localized with α -Sma in the vascular tissue, suggesting vascular fibroblasts
5 as the main producer of Fcgbp. Therefore, we cultured human vascular fibroblasts with
6 knocking down FCGBP, followed by mRNA expression profiling. We found
7 differentially regulated genes were enriched in the function for vascular stability. Such
8 findings support our hypothesis that down-regulated *FCGBP* expression could
9 destabilize the vascular wall, and lead to predisposition of vascular injury in the context
10 of SAP. However, due to the concealed protein structure of FCGBP, the exploration for
11 details of underlying mechanistic pathways of FCGBP on SIH remains constrained,
12 further substantial studies with in-depth molecular experiments are warrant.

13 To further explore the translational significance of the above findings, we developed a
14 clinical classification model that demonstrated improved diagnostic capacity with the
15 inclusion of information of *FCGBP* variant, not only for SIH but also for IPN, severity
16 and mortality of AP. The FCGBP alteration could therefore, be considered as an
17 indicator or therapeutic target for SAP and extensive critical diseases, which could
18 enhance the precision of prognostic assessments, helping to stratify patients for specific
19 treatments and clinical care.

20 To our knowledge, this is the first attempt to discover novel genetic associations by
21 WES in a population of patients with AP. Here we identified strong associations of

1 exonic variant located in FCGBP with SIH, which interacted with other complications
2 and further related to the severity and mortality of AP. Those findings might direct the
3 development of highly needed therapies to prevent life-threatening complications in the
4 early phase of acute pancreatitis, thereby facilitating a more effective strategy for AP
5 prognosis and critical care.

6 Here are some limitations that require acknowledgement in our study; first, although
7 our cohort consists of a rare population of severely AP patients with SIH, the sample
8 size of our primary discovery was relatively small in terms of genetic research. By
9 applying the multi-stage analyses and experimental verification, we were able to limit
10 our sample size and still be able to detect true differences between the phenotypes;
11 second, while this study represented large-scale AP patients transferred from multi
12 centers across China, our analyses were still limited by lack of external validation. The
13 correlation between genetic alterations and clinicopathological characteristics, should
14 still be fully validated in an independent population; third, because of the retrospective
15 study design, residual bias could not be fully eliminated. Nevertheless, through
16 stringent clinical assessment by well-trained doctors and precise laboratory measures,
17 the results affected by residual bias would be minimized. The retrospective nature of
18 such study also resulted in that some of the sample quality failed to fully meet the
19 criteria of sequencing, that is, the bias of WES quality could not be completely ruled
20 out. In addition, due to the technical and annotated limit of WES, the structural variants
21 (e.g., copy number variants) were difficult to accurately capture; fourth, the current

1 study was conducted in a predominantly Chinese population, therefore, findings should
2 be implemented with caution when generalized to other ethnicities; fifth, despite we
3 carefully matched our population, it is possible that other unmeasured factors were
4 responsible for the observed difference in allele frequency and alter our results; sixth,
5 even though the *Fcgbp-KD* mouse model provided sufficient *in-vivo* verification for
6 populational observation of *FCGBP* variant, the use of *Fcgbp* knockout (*Fcgbp*^{-/-})
7 mouse model might augment the experimental evidence. However, the necessity of
8 using *Fcgbp* knockout (*Fcgbp*^{-/-}) mouse model still remained dispute with consideration
9 of the against on the uncertainty of function of *FCGBP* variant and the mitigation of
10 suffering for experimental animals; seventh, due to the unknown *FCGBP* gene structure
11 and its protein structure, the demonstration in terms of the formality caused by *FCGBP*
12 variant is impeded, thereby future structural biological research is warrant. finally,
13 while we are only beginning to dissect the genomic architecture that drives
14 complication (i.e., SIH) in AP with a hypothesized mechanism, this study adds
15 considerable insights and provides leads for further functional analyses or targets for
16 therapies in the context of AP, and deserves to expand to other complications.
17

1 **Acknowledgments**

2 This research was funded by the National Natural Science Foundation of China
3 (8207035023, 82204033), Natural Science Foundation of Jiangsu Province
4 (BK20220826). Dr. E.YW.Yu is recipient of the Zhishan Young Scholar Award at the
5 Southeast University (2242023R40031). The authors acknowledge that certain figures
6 were created, adapted and exported from BioRender.com (2023). Retrieved from
7 <https://app.biorender.com/biorender-templates>.

8

1 **References**

- 2 1. Petrov MS, Yadav D. Global epidemiology and holistic prevention of pancreatitis.
3 *Nat Rev Gastroenterol Hepatol* 2019; **16**(3): 175-84.
- 4 2. Boxhoorn L, Voermans RP, Bouwense SA, et al. Acute pancreatitis. *Lancet* 2020;
5 **396**(10252): 726-34.
- 6 3. Xiao AY, Tan ML, Wu LM, et al. Global incidence and mortality of pancreatic
7 diseases: a systematic review, meta-analysis, and meta-regression of population-based
8 cohort studies. *Lancet Gastroenterol Hepatol* 2016; **1**(1): 45-55.
- 9 4. van Dijk SM, Hallensleben NDL, van Santvoort HC, et al. Acute pancreatitis:
10 recent advances through randomised trials. *Gut* 2017; **66**(11): 2024-32.
- 11 5. Flati G, Andrén-Sandberg A, La Pinta M, Porowska B, Carboni M. Potentially fatal
12 bleeding in acute pancreatitis: pathophysiology, prevention, and treatment. *Pancreas*
13 2003; **26**(1): 8-14.
- 14 6. Chen Y, Zhou J, Li G, et al. Early Spontaneous Abdominal Bleeding is associated
15 with Poor Outcome in Moderate to Severe Acute Pancreatitis Patients: A Propensity
16 Matched Study. *Sci Rep* 2017; **7**: 42607.
- 17 7. van den Berg FF, Issa Y, Vreijling JP, et al. Whole-Exome Sequencing Identifies
18 SLC52A1 and ZNF106 Variants as Novel Genetic Risk Factors for (Early) Multiple-
19 Organ Failure in Acute Pancreatitis. *Ann Surg* 2021;
- 20 8. Bishehsari F, Sharma A, Stello K, et al. TNF-alpha gene (TNFA) variants increase
21 risk for multi-organ dysfunction syndrome (MODS) in acute pancreatitis.
22 *Pancreatology* 2012; **12**(2): 113-8.
- 23 9. de-Madaria E, Martínez J, Sempere L, et al. Cytokine genotypes in acute
24 pancreatitis: association with etiology, severity, and cytokine levels in blood. *Pancreas*
25 2008; **37**(3): 295-301.
- 26 10. Liu Y, Dan G, Wu L, et al. Functional effect of polymorphisms in the promoter of
27 TNFAIP3 (A20) in acute pancreatitis in the Han Chinese population. *PLoS One* 2014;
28 **9**(7): e103104.

- 1 11. Zhang DL, Zheng HM, Yu BJ, Jiang ZW, Li JS. Association of polymorphisms of
2 IL and CD14 genes with acute severe pancreatitis and septic shock. *World J*
3 *Gastroenterol* 2005; **11**(28): 4409-13.
- 4 12. Posey JE, Harel T, Liu P, et al. Resolution of Disease Phenotypes Resulting from
5 Multilocus Genomic Variation. *N Engl J Med* 2017; **376**(1): 21-31.
- 6 13. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis--2012:
7 revision of the Atlanta classification and definitions by international consensus. *Gut*
8 2013; **62**(1): 102-11.
- 9 14. Dellinger EP, Forsmark CE, Layer P, et al. Determinant-based classification of
10 acute pancreatitis severity: an international multidisciplinary consultation. *Ann Surg*
11 2012; **256**(6): 875-80.
- 12 15. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-
13 generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience*
14 2015; **4**: 7.
- 15 16. Marees AT, de Kluiver H, Stringer S, et al. A tutorial on conducting genome-wide
16 association studies: Quality control and statistical analysis. *Int J Methods Psychiatr Res*
17 2018; **27**(2): e1608.
- 18 17. Ionita-Laza I, Lee S, Makarov V, Buxbaum JD, Lin X. Sequence kernel association
19 tests for the combined effect of rare and common variants. *Am J Hum Genet* 2013; **92**(6):
20 841-53.
- 21 18. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing
22 for sequencing data with the sequence kernel association test. *Am J Hum Genet* 2011;
23 **89**(1): 82-93.
- 24 19. Zhou X, Liu Z, Cheng X, Zheng Y, Zeng F, He Y. Socs1 and Socs3 degrades Traf6
25 via polyubiquitination in LPS-induced acute necrotizing pancreatitis. *Cell Death Dis*
26 2015; **6**(12): e2012.
- 27 20. Schmidt J, Rattner DW, Lewandrowski K, et al. A better model of acute pancreatitis
28 for evaluating therapy. *Ann Surg* 1992; **215**(1): 44-56.

- 1 21. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+
2 to analyze and compare ROC curves. *BMC Bioinformatics* 2011; **12**: 77.
- 3 22. Demler OV, Pencina MJ, D'Agostino RB, Sr. Misuse of DeLong test to compare
4 AUCs for nested models. *Stat Med* 2012; **31**(23): 2577-87.
- 5 23. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general
6 framework for estimating the relative pathogenicity of human genetic variants. *Nat*
7 *Genet* 2014; **46**(3): 310-5.
- 8 24. Harada N, Iijima S, Kobayashi K, et al. Human IgGFc binding protein
9 (FcgammaBP) in colonic epithelial cells exhibits mucin-like structure. *J Biol Chem*
10 1997; **272**(24): 15232-41.
- 11 25. O'Donovan N, Fischer A, Abdo EM, et al. Differential expression of IgG Fc binding
12 protein (FcgammaBP) in human normal thyroid tissue, thyroid adenomas and thyroid
13 carcinomas. *J Endocrinol* 2002; **174**(3): 517-24.
- 14 26. Rajkumar T, Vijayalakshmi N, Gopal G, et al. Identification and validation of genes
15 involved in gastric tumorigenesis. *Cancer Cell Int* 2010; **10**: 45.
- 16 27. Yang W, Shi J, Zhou Y, et al. Integrating proteomics and transcriptomics for the
17 identification of potential targets in early colorectal cancer. *Int J Oncol* 2019; **55**(2):
18 439-50.
- 19 28. Xiong L, Wen Y, Miao X, Yang Z. NT5E and FcGBP as key regulators of TGF-1-
20 induced epithelial-mesenchymal transition (EMT) are associated with tumor
21 progression and survival of patients with gallbladder cancer. *Cell Tissue Res* 2014;
22 **355**(2): 365-74.
- 23 29. Gäbel G, Northoff BH, Weinzierl I, et al. Molecular Fingerprint for Terminal
24 Abdominal Aortic Aneurysm Disease. *J Am Heart Assoc* 2017; **6**(12).
- 25 30. Zhang M, Ding X, Zhang Q, et al. Exome sequencing of 112 trios identifies
26 recessive genetic variants in brain arteriovenous malformations. *J Neurointerv Surg*
27 2021; **13**(6): 568-73.

28

Table 1 Demographical and clinical characteristics of participants ^a

	Overall (n=90)	SIH (n=45)	Control (n=45)	<i>p</i>
Age ^b (median (IQR))	41.00 (31.00, 49.75)	46.00 (33.00, 56.00)	38.00 (30.00, 44.00)	0.007
APACHE II (median (IQR))	15.00 (10.00, 18.75)	15.00 (10.00, 18.00)	15.00 (10.00, 19.00)	0.872
BMI (median (IQR))	25.70 (23.00, 28.41)	26.00 (23.44, 28.56)	24.95 (22.40, 28.25)	0.285
Gender (%)				
Male	61 (67.8)	37 (82.2)	24 (53.3)	0.006
Female	29 (32.2)	8 (17.8)	21 (46.7)	
Death (%)	26 (28.9)	16 (35.6)	10 (22.2)	0.245
Etiology of AP (%)				
Hypertriglyceridemia	66 (73.3)	21 (46.7)	45 (100.0)	<0.001
Biliary	20 (22.2)	20 (44.4)	0 (0.0)	
Others	4 (4.4)	4 (8.9)	0 (0.0)	
ARDS (%)	73 (81.1)	37 (82.2)	36 (80.0)	0.999
AKI (%)				
Level 3	45 (50.0)	21 (46.7)	24 (53.3)	0.181
Level 2	4 (4.4)	2 (4.4)	2 (4.4)	
Level 1	18 (20.0)	13 (28.9)	5 (11.1)	

Sepsis (%)	21 (23.3)	15 (33.3)	6 (13.3)	0.045
Hypertension (%)	16 (17.8)	12 (26.7)	4 (8.9)	0.051
Diabetes (%)	18 (20.0)	9 (20.0)	9 (20.0)	0.999
Hyperlipidemia (%)	52 (57.8)	19 (42.2)	33 (73.3)	0.005
PT (median (IQR); second)	14.45 (13.40, 15.70)	14.70 (13.60, 15.70)	14.30 (13.00, 15.70)	0.397
APTT (median (IQR); second)	34.25 (28.83, 43.95)	34.40 (28.50, 47.30)	34.00 (29.60, 41.30)	0.643
INR (median (IQR))	1.26 (1.16, 1.37)	1.27 (1.17, 1.37)	1.23 (1.13, 1.36)	0.375
TT (median (IQR); second)	16.60 (15.22, 17.90)	17.00 (15.90, 18.30)	15.70 (14.80, 17.40)	0.027
Fibrinogen (median (IQR); g/L)	4.34 (3.37, 5.22)	4.09 (2.76, 4.79)	4.56 (3.84, 5.90)	0.022
FDP (median (IQR); µg/L)	20.20 (12.00, 32.80)	20.50 (12.50, 30.10)	19.50 (11.80, 34.50)	0.928
DD-dimer (median (IQR); mg/L)	5.58 (3.18, 9.60)	5.68 (4.24, 9.60)	5.54 (3.11, 9.16)	0.688
Platelet (median (IQR); ×10⁹/L)	172.50 (111.75, 293.25)	173.00 (102.00, 304.00)	172.00 (117.00, 284.00)	0.977

^a The characteristics, i.e., APACHE II, showed no significant different after propensity matching.

^b Age at the time of recruitment.

Descriptive statistics are presented as median (IQR) for continuous characteristics, and frequency (percentage, %) for categorical characteristics. *p*-values were derived from Fisher exact test for categorical characteristics and Mann-Whitney U test for continuous characteristics.

Abbreviation: APACHE II: Acute Physiology and Chronic Health Evaluation II; BMI: Body Mass Index; ARDS: Acute Respiratory Distress Syndrome; AKI: Acute Kidney Injury; PT: Prothrombin Time; APTT: Activated Partial Thromboplastin Time; INR: International

Normalized Ratio; TT: Thrombin Time; FDP: Fibrinogen Degradation Products; IQR: interquartile range; SIH: Spontaneous Intraabdominal Hemorrhage.

Figure legends

Graphical Abstract

Fig. 1 The schematic design and workflow of participants enrollment, bioinformatics analysis, and animal experiments.

In total, 45 SIH-SAP cases, 45 primary non-SIH-SAP controls and 510 secondary non-SIH-AP controls were included in the current study. A series of analyses were performed to identify the exome variants related to SIH development. Animal experiments were used to verify the effects of identified gene on causing SIH in SAP model.

Abbreviations: MAF, minor allele frequency; RNAi-AAV, adeno-associated virus packaged with small hairpin RNA; LPS, lipopolysaccharides; PBS, phosphate buffer saline; SIH, spontaneous intraabdominal hemorrhage; AP, acute pancreatitis patients; SAP, severe acute pancreatitis.

Fig. 2 Overview of candidate variants selection and characteristics profiling.

(A) flow-chart of inclusion and exclusion of genetic variants, 1,322 exonic variants were finally selected as candidate variants. (B) genetic principal component analysis of the included participants. (C) the distribution of predicted deleterious or benign candidate variants based on karyotype according to Sorting Intolerant from Tolerant (SIFT) algorithm. The red, purple and green triangles denote probably deleterious sites, possibly deleterious sites and benign sites, respectively. (D) summary characteristics of candidate exonic variants.

Abbreviations: VQSR, variant quality score recalibration; SNV, single nucleotide variants; SNP, single nucleotide polymorphism; DEL, deletion; SIFT, Sorting Intolerant from Tolerant.

Fig. 3 Bioinformatics analyses identify *FCGBP* and its variant to be associated with SIH development.

(A) an example of computed tomography for SIH. The yellow pentagram indicates the focal lesion of SIH in an SAP patient. (B) distribution of *FCGBP* variants among SIH-SAP patients. A frameshift deletion is symbolized by a blue circle, whereas a green circle denotes an altered amino acid. (C) Manhattan plot of GWAS based on exome variants in chromosome 19. The x-axis is chromosomal position and the y-axis is $-\log_{10}(p)$ value of GWAS). The rs1326680184 was used and denoted to represent the six identified *FCGBP* variants. (D) distribution of CADD score of 1,322 candidate variants. (E) Protein sequence alignment of *FCGBP* in *Homo sapiens*, *Equus caballus*, *Mus musculus*, *Rattus norvegicus*, *Pan troglodytes*, *Macaca mulatta* and *Bos taurus*. The results revealed that the screened residues of *FCGBP* is highly conserved across multiple species and isoforms. In this alignment, residues that are absolutely conserved and highly conserved are highlighted in orange and green, respectively. (F) Gene-based variants of SAP patients. The matrix in the middle panel indicates each column representing per patient, and each row representing per gene. The bar plot on the top shows the number of variants in each individual and the bar plot on the right side shows the percentage of individuals containing a variant in each gene. The bottom plot shows the distribution of 6 types of variants per individual.

Abbreviations: MAF, minor allele frequency; RNAi-AAV, adeno-associated virus packaged with small hairpin RNA; LPS, lipopolysaccharides; PBS, phosphate buffer saline; SIH, spontaneous intraabdominal hemorrhage; AP, acute pancreatitis patients; SAP, severe acute pancreatitis;

FCGBP/Fcgbp, Fc Fragment of Immunoglobulin G Binding Protein; GWAS, genome-wide association study; CADD, combined annotation dependent depletion.

Fig. 4 *FCGBP* variant (i.e., rs1326680184) relates to lower expression of *FCGBP* in patients and *Fcgbp-KD* exacerbates the severity and lung injury of AP in mice.

(A) violin plot of protein FCGBP's concentration in peripheral blood of AP patients, compared between rs1326680181 carriers and non-carriers (n=27 in each group), * indicates $p < 0.05$ by *Student's t* test with Welch's correction. (B) western-blot upon protein Fcgbp from colon tissue of mice received *Fcgbp-KD* and normal healthy mice. (C) quantification of western-blot presents the ratio of Fcgbp/Gapdh (n=6 in each group), ** indicates $p < 0.01$ by Man-Whitney test. (D) immunohistochemical analysis demonstrates the presence of Fcgbp in mice colonic tissue. Injection of AAV-RNAi targeting Fcgbp inhibits the expression of *Fcgbp*, compared with AAV empty vector and PBS as control (n=10 in each group). (E) quantification of *Fcgbp* expression. This was measured as stained area using ImageJ, taking control group as reference. ** indicates $p < 0.01$ by one-way ANOVA with post-hoc tests. Error bars are shown as SEM. (F) morphological examination of lung and pancreas tissue (H&E staining). The results showed edema, acinar necrosis, hemorrhage and inflammation. Cellular edema and damage, infiltration of neutrophils is much severer in Fcgbp knock-down mice, and leakage of red blood cells were found in Fcgbp knock-down mice but not in the AAV empty vector injected mice and controls. (G) quantification of severity according to pathological scoring scale. * indicates $p < 0.05$, *** indicates $p < 0.001$ by one-way ANOVA with post-hoc tests. Error bars are shown as SEM (n=10 in each group).

Abbreviations: AN, acinar cell necrosis; He & FN, hemorrhage and fat necrosis; Infla, inflammation; FCGBP/Fcgbp, Fc Fragment of Immunoglobulin G Binding Protein; KD, knockdown; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RNAi-AAV, adeno-associated virus packaged with small hairpin RNA; AAV, adeno-associated virus; PBS, phosphate buffer saline; ANOVA, Analysis of variance; SEM, standard error of mean.

Fig. 5 Vascular fibroblasts produce FCGBP and function as vascular wall stabilizer.

(A) Representative immunofluorescence images of Fcgbp and α -Sma in vascular tissue which indicates the co-localization of Fcgbp and α -Sma
(B) Volcano plot of DEGs of *FCGBP*-knockdown fibroblasts. (C) The top 100 up-regulated and top 101 down-regulated DEGs of FCGBP knockdown fibroblasts were presented in the heatmap plot, with enrichment items of corresponding gene sets were presented by side. (D) A hypothetical mechanism of *FCGBP* variants (i.e., rs1326680184) affecting the predisposition of SIH in SAP: rs1326680184 carrier suffered a weak extra cellular matrix compared with non-carrier, resulting in a higher risk of vascular injury and hemorrhage under the impact of severe acute pancreatitis.

Abbreviations: FCGBP/Fcgbp, Fc Fragment of Immunoglobulin G Binding Protein; DEGs, Differentially Expressed Genes; SIH, spontaneous intraabdominal hemorrhage; SAP, severe acute pancreatitis.

Fig. 6 Associations between *FCGBP* variant (i.e., rs1326680184) and clinical characteristics.

(A) a comparison of clinical characteristics at admission between rs1326680184 variant carriers and non-variant carriers. (B) forest plots of rs1326680184 variant with the risk of SIH, critical severity of SAP, infected pancreatic necrosis, and death. The odds ratios (ORs) were shown by solid square and horizontal lines representing the 95% confidence intervals, the adjustments were performed with age, gender, BMI, and etiology of AP. (C) The receiver operating characteristic curve (ROC) and diagnostic ability of demographic and rs1326680184 variant in relation to multiple clinical characteristics. The statistical comparison was conducted using DeLong's test, which the $p < 0.05$ was considered as statistical significance.

Abbreviations: MAF, minor allele frequency; RNAi-AAV, adeno-associated virus packaged with small hairpin RNA; LPS, lipopolysaccharides; PBS, phosphate buffer saline; SIH, spontaneous intraabdominal hemorrhage; AP, acute pancreatitis patients; SAP, severe acute pancreatitis; ORs, odds ratios; BMI, body mass index; ROC, receiver operating characteristic curve.

Graphical Abstract




Fig. 1 The schematic design and workflow of participants enrollment, bioinformatics analysis, and animal experiments.




Fig. 2 Overview of candidate variants selection and characteristics profiling.




Fig. 3 Bioinformatics analyses identify *FCGBP* and its variant to be associated with SIH development.




Fig. 4 *FCGBP* variant (i.e., rs1326680184) relates to lower expression of *FCGBP* in patients and *Fcgbp-KD* exacerbates the severity and lung injury of AP in mice.




Fig. 5 Vascular fibroblasts produce FCGBP and function as vascular wall stabilizer.




Fig. 6 Associations between *FCGBP* variant (i.e., rs1326680184) and clinical characteristics.

